{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,12]],"date-time":"2026-10-12T02:34:37Z","timestamp":1791772477624,"version":"4.3.4"},"reference-count":161,"publisher":"MDPI AG","issue":"1","license":[{"start":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T00:00:00Z","timestamp":1767139200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006742","name":"CESPU\u2014Cooperativa de Ensino Superior Polit\u00e9cnico e Universit\u00e1rio Crl","doi-asserted-by":"publisher","award":["UNICORN-GI2-CESPU-2025"],"award-info":[{"award-number":["UNICORN-GI2-CESPU-2025"]}],"id":[{"id":"10.13039\/501100006742","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Inflammatory bowel disease is a result of inappropriate continuous non-specific inflammation in the intestinal tract, which in turn is aggravated by defects in the activation of the mucosal immune system and in the barrier function of the intestinal epithelium. The most prominent manifestations of IBD are ulcerative colitis (UC) and Crohn\u2019s disease (CD). UC is characterized by a continuous pattern that commonly starts with lesions in rectum mucosa and is contained in the colon. On the other hand, CD affects the ileum and colon in a discontinuous pattern, and the lesions are often transmural. Conventional therapies often face limitations such as systemic side effects, poor drug stability, and low site-specificity. In recent years, nanoparticle (NP) systems have emerged as a promising strategy to overcome these challenges, offering improved targeting, controlled release, and enhanced therapeutic efficacy. Several studies have shown that the preferential accumulation of NPs in the inflamed colon is influenced by the pathophysiological changes associated with IBD, including alterations in transit time, pH value, enzymatic activity, microbial composition, and mucus integrity. These disease-specific characteristics provide unique opportunities to design smart and responsive NPs that enhance drug delivery and therapeutic efficacy while minimizing systemic exposure. This work presents an overview of novel technologies based on nanosystems, with the ability to specifically target the affected areas of the GI tract in inflammatory bowel disease.<\/jats:p>","DOI":"10.3390\/pharmaceutics18010055","type":"journal-article","created":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T16:34:23Z","timestamp":1767198863000},"page":"55","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["Selective Nanoparticulate Systems for Drug Delivery in Inflammatory Bowel Disease"],"prefix":"10.3390","volume":"18","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-8324-8347","authenticated-orcid":false,"given":"Alberta","family":"Ribeiro","sequence":"first","affiliation":[{"name":"IUCS\u2014University Institute of Health Sciences, Cooperativa de Ensino Superior Polit\u00e9cnico e Universit\u00e1rio (CESPU), Rua Central de Gandra, 1317, 4585-116 Gandra, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8633-4404","authenticated-orcid":false,"given":"Rute","family":"Nunes","sequence":"additional","affiliation":[{"name":"IUCS\u2014University Institute of Health Sciences, Cooperativa de Ensino Superior Polit\u00e9cnico e Universit\u00e1rio (CESPU), Rua Central de Gandra, 1317, 4585-116 Gandra, Portugal"},{"name":"UNIPRO\u2014Oral Pathology and Rehabilitation Research Unit, University Institute of Health Sciences (IUCS), Cooperativa de Ensino Superior Polit\u00e9cnico e Universit\u00e1rio (CESPU), Rua Central de Gandra, 1317, 4585-116 Gandra, Portugal"},{"name":"i3S\u2014Instituto de Investiga\u00e7\u00e3o e Inova\u00e7\u00e3o em Sa\u00fade, Universidade do Porto, Rua Alfredo Allen 208, 4200-135 Porto, Portugal"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2025,12,31]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/S2468-1253(19)30333-4","article-title":"The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990\u20132017: A systematic analysis for the Global Burden of Disease Study 2017","volume":"5","author":"Alatab","year":"2020","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1038\/nrgastro.2015.150","article-title":"The global burden of IBD: From 2015 to 2025","volume":"12","author":"Kaplan","year":"2015","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.crohns.2013.01.010","article-title":"The burden of inflammatory bowel disease in Europe","volume":"7","author":"Burisch","year":"2013","journal-title":"J. Crohns Colitis"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2101","DOI":"10.1053\/j.gastro.2010.01.058","article-title":"Inflammation and Colon Cancer","volume":"138","author":"Grivennikov","year":"2010","journal-title":"Gastroenterology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1056\/NEJMra020831","article-title":"Inflammatory Bowel Disease","volume":"347","author":"Podolsky","year":"2002","journal-title":"N. Engl. J. Med."},{"key":"ref_6","doi-asserted-by":"crossref","unstructured":"Imbrizi, M., Magro, F., and Coy, C.S.R. (2023). Pharmacological therapy in inflammatory bowel diseases: A narrative review of the past 90 years. Pharmaceuticals, 16.","DOI":"10.3390\/ph16091272"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"2544689","DOI":"10.1080\/10717544.2025.2544689","article-title":"Advances in oral treatment of inflammatory bowel disease using protein-based nanoparticle drug delivery systems","volume":"32","author":"Lin","year":"2025","journal-title":"Drug Deliv."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1038\/nature06005","article-title":"Unravelling the pathogenesis of inflammatory bowel disease","volume":"448","author":"Xavier","year":"2007","journal-title":"Nature"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1038\/nature10209","article-title":"Genetics and pathogenesis of inflammatory bowel disease","volume":"474","author":"Khor","year":"2011","journal-title":"Nature"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1038\/ng.3359","article-title":"Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations","volume":"47","author":"Liu","year":"2015","journal-title":"Nat. Genet."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1038\/nm.2069","article-title":"NOD2 stimulation induces autophagy in dendritic cells influencing bacterial handling and antigen presentation","volume":"16","author":"Cooney","year":"2010","journal-title":"Nat. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1038\/35079114","article-title":"A frameshift mutation in NOD2 associated with susceptibility to Crohn\u2019s disease","volume":"411","author":"Ogura","year":"2001","journal-title":"Nature"},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.1056\/NEJMra0804647","article-title":"Inflammatory Bowel Disease","volume":"361","author":"Abraham","year":"2009","journal-title":"N. Engl. J. Med."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1053\/j.gastro.2019.04.016","article-title":"Environmental Risk Factors for Inflammatory Bowel Diseases: An Umbrella Review of Meta-analyses","volume":"157","author":"Piovani","year":"2019","journal-title":"Gastroenterology"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1001\/jamapediatrics.2017.2571","article-title":"The role of environmental factors in the pathogenesis of inflammatory bowel diseases: A review","volume":"171","author":"Shouval","year":"2017","journal-title":"JAMA Pediatr."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"1662","DOI":"10.1093\/ecco-jcc\/jjaa114","article-title":"Identification of environmental risk factors associated with the development of inflammatory bowel disease","volume":"14","author":"Weersma","year":"2020","journal-title":"J. Crohns Colitis"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"19273","DOI":"10.1038\/s41598-020-76361-2","article-title":"Identifying environmental risk factors for inflammatory bowel diseases: A Mendelian randomization study","volume":"10","author":"Duell","year":"2020","journal-title":"Sci. Rep."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1053\/j.gastro.2013.07.050","article-title":"A prospective study of long-term intake of dietary fiber and risk of Crohn\u2019s disease and ulcerative colitis","volume":"145","author":"Ananthakrishnan","year":"2013","journal-title":"Gastroenterology"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1136\/gutjnl-2013-305304","article-title":"Long-term intake of dietary fat and risk of ulcerative colitis and Crohn\u2019s disease","volume":"63","author":"Ananthakrishnan","year":"2014","journal-title":"Gut"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1038\/s41575-018-0022-9","article-title":"The role of diet in the aetiopathogenesis of inflammatory bowel disease","volume":"15","author":"Khalili","year":"2018","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Lee, S.H., Yun, Y., Kim, S.J., Lee, E.J., Chang, Y., Ryu, S., Shin, H., Kim, H.-L., Kim, H.-N., and Lee, J.H. (2018). Association between Cigarette Smoking Status and Composition of Gut Microbiota: Population-Based Cross-Sectional Study. J. Clin. Med., 7.","DOI":"10.3390\/jcm7090282"},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"John, H.T., Thomas, T.C., Chukwuebuka, E.C., Ali, A.B., Anass, R., Tefera, Y.Y., Babu, B., Negrut, N., Ferician, A., and Marian, P. (2025). The Microbiota\u2013Human Health Axis. Microorganisms, 13.","DOI":"10.3390\/microorganisms13040948"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"13780","DOI":"10.1073\/pnas.0706625104","article-title":"Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases","volume":"104","author":"Frank","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"91","DOI":"10.3748\/wjg.v20.i1.91","article-title":"Inflammatory bowel disease: Pathogenesis","volume":"20","author":"Zhang","year":"2014","journal-title":"World J. Gastroenterol. WJG"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.3748\/wjg.v29.i14.2078","article-title":"Role of prebiotics, probiotics, and synbiotics in management of inflammatory bowel disease: Current perspectives","volume":"29","author":"Roy","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Weng, M.T., Hsiung, C.Y., Wei, S.C., and Chen, Y. (2024). Nanotechnology for targeted inflammatory bowel disease therapy: Challenges and opportunities. Wiley Interdiscip. Rev. Nanomed. Nanobiotechnol., 16.","DOI":"10.1002\/wnan.1999"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Diez-Martin, E., Hernandez-Suarez, L., Mu\u00f1oz-Villafranca, C., Martin-Souto, L., Astigarraga, E., Ramirez-Garcia, A., and Barreda-G\u00f3mez, G. (2024). Inflammatory bowel disease: A comprehensive analysis of molecular bases, predictive biomarkers, diagnostic methods, and therapeutic options. Int. J. Mol. Sci., 25.","DOI":"10.3390\/ijms25137062"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"4264","DOI":"10.3748\/wjg.v16.i34.4264","article-title":"Intestinal epithelial cells in inflammatory bowel diseases","volume":"16","author":"Roda","year":"2010","journal-title":"World J. Gastroenterol. WJG"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.jcmgh.2017.03.007","article-title":"Mend your fences: The epithelial barrier and its relationship with mucosal immunity in inflammatory bowel disease","volume":"4","author":"Martini","year":"2017","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1146\/annurev-immunol-030409-101225","article-title":"Inflammatory bowel disease","volume":"28","author":"Kaser","year":"2010","journal-title":"Annu. Rev. Immunol."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41577-022-00792-3","article-title":"Death by TNF: A road to inflammation","volume":"23","author":"Bertrand","year":"2023","journal-title":"Nat. Rev. Immunol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"2733","DOI":"10.3748\/wjg.v29.i18.2733","article-title":"Study of tumor necrosis factor receptor in the inflammatory bowel disease","volume":"29","author":"Souza","year":"2023","journal-title":"World J. Gastroenterol."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1159\/000540421","article-title":"Antibodies targeting the tumor necrosis factor-like ligand 1A in inflammatory bowel disease: A new hid on the (biologics) block?","volume":"105","author":"Schweckendiek","year":"2024","journal-title":"Digestion"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1136\/gutjnl-2024-332504","article-title":"Targeting TL1A and DR3: The new frontier of anti-cytokine therapy in IBD","volume":"74","author":"Bamias","year":"2025","journal-title":"Gut"},{"key":"ref_35","doi-asserted-by":"crossref","unstructured":"Alhendi, A., and Naser, S.A. (2023). The dual role of interleukin-6 in Crohn\u2019s disease pathophysiology. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1295230"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"289","DOI":"10.2147\/ITT.S282466","article-title":"All are Equal, Some are more equal: Targeting IL 12 and 23 in IBD\u2014A Clinical Perspective","volume":"9","author":"Jefremow","year":"2020","journal-title":"Immuno Targets Ther."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"ii64","DOI":"10.1093\/ecco-jcc\/jjab185","article-title":"Blockade of IL-23: What is in the Pipeline?","volume":"16","author":"Parigi","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.cytogfr.2022.07.005","article-title":"The involvement of TH17 cells in the pathogenesis of IBD","volume":"69","author":"Jiang","year":"2023","journal-title":"Cytokine Growth Factor Rev."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"5853","DOI":"10.1039\/D2TB01190E","article-title":"Nanoparticles for oral delivery: Targeted therapy for inflammatory bowel disease","volume":"10","author":"Li","year":"2022","journal-title":"J. Mater. Chem. B"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijpharm.2008.05.012","article-title":"Gut instincts: Explorations in intestinal physiology and drug delivery","volume":"364","author":"McConnell","year":"2008","journal-title":"Int. J. Pharm."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1007\/s12272-020-01219-0","article-title":"Advances in colon-targeted nano-drug delivery systems: Challenges and solutions","volume":"43","author":"Naeem","year":"2020","journal-title":"Arch. Pharm. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/j.jconrel.2021.04.026","article-title":"Oral delivery of micro\/nanoparticulate systems based on natural polysaccharides for intestinal diseases therapy: Challenges, advances and future perspectives","volume":"334","author":"Carvalho","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"51","DOI":"10.4161\/gmic.1.1.10470","article-title":"The inner of the two Muc2 mucin-dependent mucus layers in colon is devoid of bacteria","volume":"1","author":"Hansson","year":"2010","journal-title":"Gut Microbes"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"4659","DOI":"10.1073\/pnas.1006451107","article-title":"The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host\u2013microbial interactions","volume":"108","author":"Johansson","year":"2011","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"2142","DOI":"10.1136\/gutjnl-2018-317571","article-title":"Structural weakening of the colonic mucus barrier is an early event in ulcerative colitis pathogenesis","volume":"68","author":"Birchenough","year":"2019","journal-title":"Gut"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"103717","DOI":"10.1016\/j.autrev.2024.103717","article-title":"Intestinal mucus barrier: A potential therapeutic target for IBD","volume":"24","author":"Qiao","year":"2025","journal-title":"Autoimmun. Rev."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.nantod.2017.08.006","article-title":"Nanoparticulate Drug Delivery Systems Targeting Inflammation for Treatment of Inflammatory Bowel Disease","volume":"16","author":"Zhang","year":"2017","journal-title":"Nano Today"},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"106560","DOI":"10.1016\/j.micpath.2024.106560","article-title":"The proteolytic activity in inflammatory bowel disease: Insight from gut microbiota","volume":"188","author":"Hou","year":"2024","journal-title":"Microb. Pathog."},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/ecco-jcc\/jjad178","article-title":"Matrix metalloproteinases in intestinal fibrosis","volume":"18","author":"Biel","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"ref_50","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.2147\/JIR.S288280","article-title":"Metalloproteinases in Inflammatory Bowel Diseases","volume":"14","author":"Marafini","year":"2021","journal-title":"J. Inflamm. Res."},{"key":"ref_51","doi-asserted-by":"crossref","unstructured":"Coskun, M. (2014). Intestinal epithelium in inflammatory bowel disease. Front. Med., 1.","DOI":"10.3389\/fmed.2014.00024"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"4306","DOI":"10.1007\/s10620-023-08122-w","article-title":"Intestinal barrier dysfunction in inflammatory bowel disease: Underpinning pathogenesis and therapeutics","volume":"68","author":"Dunleavy","year":"2023","journal-title":"Dig. Dis. Sci."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1002\/ibd.20539","article-title":"Intestinal barrier dysfunction in inflammatory bowel diseases","volume":"15","author":"McGuckin","year":"2009","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.mayocp.2018.09.013","article-title":"Mechanisms of Disease: Inflammatory bowel diseases","volume":"94","author":"Ramos","year":"2019","journal-title":"Mayo Clin. Proc."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"109466","DOI":"10.1016\/j.intimp.2022.109466","article-title":"The role of NOD2 in intestinal immune response and microbiota modulation: A therapeutic target in inflammatory bowel disease","volume":"113","author":"Liu","year":"2022","journal-title":"Int. Immunopharmacol."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"903","DOI":"10.1136\/gut.2007.142588","article-title":"Reduced alpha-defensin expression is associated with inflammation and not NOD2 mutation status in ileal Crohn\u2019s disease","volume":"57","author":"Simms","year":"2008","journal-title":"Gut"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"18129","DOI":"10.1073\/pnas.0505256102","article-title":"Reduced paneth cell \u03b1-defensins in ileal Crohn\u2019s disease","volume":"102","author":"Wehkamp","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Nakai, D., and Miyake, M. (2023). Intestinal Membrane Function in Inflammatory Bowel Disease. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16010029"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"883","DOI":"10.7326\/0003-4819-105-6-883","article-title":"Increased intestinal permeability in patients with Crohn\u2019s disease and their relatives. A possible etiologic factor","volume":"105","author":"Hollander","year":"1986","journal-title":"Ann. Intern. Med."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1016\/0016-5085(89)91499-6","article-title":"Intestinal permeability in patients with Crohn\u2019s disease and their healthy relatives","volume":"97","author":"Katz","year":"1989","journal-title":"Gastroenterology"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1136\/gut.35.1.68","article-title":"Intestinal permeability in patients with Crohn\u2019s disease and ulcerative colitis and their first degree relatives","volume":"35","author":"Munkholm","year":"1994","journal-title":"Gut"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1136\/gut.33.3.320","article-title":"Intestinal permeability in patients with Crohn\u2019s disease and their first degree relatives","volume":"33","author":"Teahon","year":"1992","journal-title":"Gut"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jaci.2009.05.038","article-title":"Intestinal barrier function: Molecular regulation and disease pathogenesis","volume":"124","author":"Groschwitz","year":"2009","journal-title":"J. Allergy Clin. Immunol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1113\/jphysiol.2011.224568","article-title":"Determinants of colonic barrier function in inflammatory bowel disease and potential therapeutics","volume":"590","author":"Hering","year":"2012","journal-title":"J. Physiol."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"E396","DOI":"10.1055\/a-1073-7653","article-title":"Defining gastrointestinal transit time using video capsule endoscopy: A study of healthy subjects","volume":"8","author":"Murphy","year":"2020","journal-title":"Endosc. Int. Open"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1111\/nmo.12713","article-title":"Regional gastrointestinal transit times in severe ulcerative colitis","volume":"28","author":"Haase","year":"2016","journal-title":"Neurogastroenterol. Motil."},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Anbazhagan, A.N., Priyamvada, S., Alrefai, W.A., and Dudeja, P.K. (2018). Pathophysiology of IBD associated diarrhea. Tissue Barriers, 6.","DOI":"10.1080\/21688370.2018.1463897"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Zhang, Y., Wang, T., Sun, M., Song, Y., Huang, X., Zhang, S., Yang, J., and Zhang, J. (2023). Advanced nanomedicine: Redefining therapeutic paradigms for inflammatory bowel disease. Adv. Healthc. Mater., 12.","DOI":"10.1002\/adhm.202300069"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2078","DOI":"10.1007\/BF02093613","article-title":"Increased oxidative stress and decreased antioxidant defenses in mucosa of inflammatory bowel disease","volume":"41","author":"Powell","year":"1996","journal-title":"Dig. Dis. Sci."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1136\/gut.34.9.1191","article-title":"Increased production of luminol enhanced chemiluminescence by the inflamed colonic mucosa in patients with ulcerative colitis","volume":"34","author":"Sedghi","year":"1993","journal-title":"Gut"},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0016-5085(92)91111-G","article-title":"Excessive production of reactive oxygen metabolites by inflamed colon: Analysis by chemiluminescence probe","volume":"103","author":"Keshavarzian","year":"1992","journal-title":"Gastroenterology"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0016-5085(92)91112-H","article-title":"Chemiluminescence assay of mucosal reactive oxygen metabolites in inflammatory bowel disease","volume":"103","author":"Nj","year":"1992","journal-title":"Gastroenterology"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.jconrel.2023.05.007","article-title":"Wielding the double-edged sword: Redox drug delivery systems for inflammatory bowel disease","volume":"358","author":"Chen","year":"2023","journal-title":"J. Control. Release"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"1531","DOI":"10.1093\/ecco-jcc\/jjae091","article-title":"ECCO Guidelines on Therapeutics in Crohn\u2019s Disease: Medical Treatment","volume":"18","author":"Gordon","year":"2024","journal-title":"J. Crohns Colitis"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"1827","DOI":"10.1053\/j.gastro.2011.02.045","article-title":"Conventional medical management of inflammatory bowel disease","volume":"140","author":"Burger","year":"2011","journal-title":"Gastroenterology"},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Becker, H.E.F., Demers, K., Derijks, L.J.J., Jonkers, D.M.A.E., and Penders, J. (2023). Current evidence and clinical relevance of drug-microbiota interactions in inflammatory bowel disease. Front. Microbiol., 14.","DOI":"10.3389\/fmicb.2023.1107976"},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/ecco-jcc\/jjab178","article-title":"ECCO Guidelines on Therapeutics in Ulcerative Colitis: Medical Treatment","volume":"16","author":"Raine","year":"2022","journal-title":"J. Crohns Colitis"},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.addr.2013.10.001","article-title":"Drug delivery strategies in the therapy of inflammatory bowel disease","volume":"71","author":"Schmidt","year":"2014","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1039\/D3TB02302H","article-title":"Orally-administered nanomedicine systems targeting colon inflammation for the treatment of inflammatory bowel disease: Latest advances","volume":"12","author":"Hu","year":"2024","journal-title":"J. Mater. Chem. B"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"102850","DOI":"10.1016\/j.eclinm.2024.102850","article-title":"Designing for medication adherence in inflammatory bowel disease: Multi-disciplinary approaches for self-administrable biotherapeutics","volume":"77","author":"Feig","year":"2024","journal-title":"EClinicalMedicine"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1016\/j.jconrel.2022.12.029","article-title":"Colonic drug delivery: Formulating the next generation of colon-targeted therapeutics","volume":"353","author":"McCoubrey","year":"2023","journal-title":"J. Control. Release"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/j.addr.2004.08.007","article-title":"Topical delivery of therapeutic agents in the treatment of inflammatory bowel disease","volume":"57","author":"Klotz","year":"2005","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1111\/j.1365-2036.1993.tb00080.x","article-title":"Review article: Topical corticosteroids in inflammatory bowel disease","volume":"7","author":"Mulder","year":"1993","journal-title":"Aliment. Pharmacol. Ther."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"2921","DOI":"10.2147\/DDDT.S461977","article-title":"Nanoparticle-based drug delivery systems for inflammatory bowel disease Treatment","volume":"18","author":"Gao","year":"2024","journal-title":"Drug Des. Dev. Ther."},{"key":"ref_85","doi-asserted-by":"crossref","unstructured":"Cai, Z., Wang, S., and Li, J. (2021). Treatment of inflammatory bowel disease: A comprehensive review. Front. Med., 8.","DOI":"10.3389\/fmed.2021.765474"},{"key":"ref_86","doi-asserted-by":"crossref","unstructured":"Nedelcu, A., Mosteanu, O., Pop, T., Mocan, T., and Mocan, L. (2021). Recent advances in nanoparticle-mediated treatment of inflammatory bowel diseases. Appl. Sci., 11.","DOI":"10.3390\/app11010438"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5505","DOI":"10.1021\/acs.chemrev.3c00705","article-title":"Polymeric nanoparticles for drug delivery","volume":"124","author":"Beach","year":"2024","journal-title":"Chem. Rev."},{"key":"ref_88","first-page":"100305","article-title":"Exploring the landscape of Lipid Nanoparticles (LNPs): A comprehensive review of LNPs types and biological sources of lipids","volume":"8","author":"Alfutaimani","year":"2024","journal-title":"Int. J. Pharm. X"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1007\/s42247-021-00335-x","article-title":"Review on metal nanoparticles as nanocarriers: Current challenges and perspectives in drug delivery systems","volume":"5","author":"Chandrakala","year":"2022","journal-title":"Emergent Mater."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"2232248","DOI":"10.1080\/21688370.2023.2232248","article-title":"Exosomes: Current knowledge and future perspectives","volume":"12","author":"Singh","year":"2024","journal-title":"Tissue Barriers"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1016\/j.jconrel.2020.10.020","article-title":"Challenges in the development and establishment of exosome-based drug delivery systems","volume":"329","author":"Wang","year":"2021","journal-title":"J. Control. Release"},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Joseph, T., Kar Mahapatra, D., Esmaeili, A., Piszczyk, \u0141., Hasanin, M., Kattali, M., Haponiuk, J., and Thomas, S. (2023). Nanoparticles: Taking a unique position in medicine. Nanomaterials, 13.","DOI":"10.3390\/nano13030574"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"2930","DOI":"10.1007\/s13346-023-01363-2","article-title":"Targeted delivery of budesonide in acetic acid induced colitis: Impact on miR-21 and E-cadherin expression","volume":"13","author":"Seoudi","year":"2023","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"5109","DOI":"10.1021\/acsabm.5c00439","article-title":"Cyclosporine A-Loaded Poly(ethylene glycol)-block-poly(lactic-co-glycolic acid)-Based Mucopenetrating Nanoparticles for Treatment of Inflammatory Bowel Diseases","volume":"8","author":"Sato","year":"2025","journal-title":"ACS Appl. Bio Mater."},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Stalder, T., Moulari, B., Cornu, R., Chatelain, J., Koenig, N., Hassan, A., Chretien, C., Boidot, R., Richard, C., and Pellequer, Y. (2025). Targeted oral delivery of microencapsulated TNF-\u03b1 siRNA in an experimental model of colitis. Drug Deliv. Transl. Res.","DOI":"10.1007\/s13346-025-01936-3"},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"7682","DOI":"10.1038\/s41467-025-63037-6","article-title":"Targeting intestinal inflammation using locked nucleic acids delivered via lipid nanoparticles","volume":"16","author":"Qassem","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"10356","DOI":"10.1039\/D4NR04994B","article-title":"CT imaging of and therapy for inflammatory bowel disease via low molecular weight dextran coated ceria nanoparticles","volume":"17","author":"Pang","year":"2025","journal-title":"Nanoscale"},{"key":"ref_98","doi-asserted-by":"crossref","unstructured":"Koh, H.B., Kim, H.J., Kang, S.W., and Yoo, T.H. (2023). Exosome-based drug delivery: Translation from bench to clinic. Pharmaceutics, 15.","DOI":"10.3390\/pharmaceutics15082042"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/s41392-023-01704-0","article-title":"Clinical applications of stem cell-derived exosomes","volume":"9","author":"Tan","year":"2024","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1016\/j.intimp.2018.12.043","article-title":"Extracellular vesicles containing miR-146a attenuate experimental colitis by targeting TRAF6 and IRAK1","volume":"68","author":"Wu","year":"2019","journal-title":"Int. Immunopharmacol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.jconrel.2012.01.028","article-title":"Nano- and microparticulate drug carriers for targeting of the inflamed intestinal mucosa","volume":"161","author":"Collnot","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"101333","DOI":"10.1016\/j.jcmgh.2024.03.005","article-title":"Unleashing the potential of oral deliverable nanomedicine in the treatment of inflammatory bowel disease","volume":"18","author":"Yang","year":"2024","journal-title":"Cell Mol. Gastroenterol. Hepatol."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"3876","DOI":"10.1016\/j.apsb.2024.06.015","article-title":"Transepithelial transport of nanoparticles in oral drug delivery: From the perspective of surface and holistic property modulation","volume":"14","author":"Zheng","year":"2024","journal-title":"Acta Pharm. Sin. B"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1186\/s12951-024-02930-6","article-title":"Intestinal nanoparticle delivery and cellular response: A review of the bidirectional nanoparticle-cell interplay in mucosa based on physiochemical properties","volume":"22","author":"Wang","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"ref_105","doi-asserted-by":"crossref","unstructured":"Jacob, E.M., Borah, A., Pillai, S.C., and Kumar, D.S. (2020). Inflammatory Bowel Disease: The Emergence of New Trends in Lifestyle and Nanomedicine as the Modern Tool for Pharmacotherapy. Nanomaterials, 10.","DOI":"10.3390\/nano10122460"},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Di Rienzo, A., Marinelli, L., Dimmito, M.P., Toto, E.C., Di Stefano, A., and Cacciatore, I. (2024). Advancements in Inflammatory Bowel Disease Management: From Traditional Treatments to Monoclonal Antibodies and Future Drug Delivery Systems. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16091185"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1016\/j.jconrel.2012.03.004","article-title":"Nanoparticle-based clodronate delivery mitigates murine experimental colitis","volume":"160","author":"Niebel","year":"2012","journal-title":"J. Control. Release"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1023\/B:PHAM.0000019298.29561.cd","article-title":"Differential adhesion of normal and inflamed rat colonic mucosa by charged liposomes","volume":"21","author":"Jubeh","year":"2004","journal-title":"Pharm. Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1080\/10611860600648429","article-title":"Local treatment of experimental colitis in the rat by negatively charged liposomes of catalase, TMN and SOD","volume":"14","author":"Jubeh","year":"2006","journal-title":"J. Drug Target."},{"key":"ref_110","first-page":"164","article-title":"Increased concentrations of eosinophilic cationic protein in whole-gut lavage fluid from children with inflammatory bowel disease","volume":"28","author":"Troncone","year":"1999","journal-title":"J. Pediatr. Gastroenterol. Nutr."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1016\/j.addr.2011.12.009","article-title":"Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers","volume":"64","author":"Ensign","year":"2012","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"100110","DOI":"10.1016\/j.medidd.2021.100110","article-title":"Engineering nanoparticles to overcome the mucus barrier for drug delivery: Design, evaluation and state-of-the-art","volume":"12","author":"Liu","year":"2021","journal-title":"Med. Drug Discov."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1016\/j.jconrel.2014.10.026","article-title":"Effect of surface chemistry on nanoparticle interaction with gastrointestinal mucus and distribution in the gastrointestinal tract following oral and rectal administration in the mouse","volume":"197","author":"Maisel","year":"2015","journal-title":"J. Controll. Release"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.biomaterials.2018.09.005","article-title":"Mucus-penetrating budesonide nanosuspension enema for local treatment of inflammatory bowel disease","volume":"185","author":"Date","year":"2018","journal-title":"Biomaterials"},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"113948","DOI":"10.1016\/j.jconrel.2025.113948","article-title":"Oral delivery of tunable oxidation-responsive budesonide-loaded nanoparticles enhances inflammation modulation in intestinal colitis","volume":"384","author":"Cristelo","year":"2025","journal-title":"J. Controll. Release"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"2402502","DOI":"10.1002\/smll.202402502","article-title":"Orally delivered stimulus-sensitive nanomedicine to harness teduglutide efficacy in inflammatory bowel disease","volume":"20","author":"Barros","year":"2024","journal-title":"Small"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1016\/j.actbio.2021.12.015","article-title":"Impact of PEGylation on an antibody-loaded nanoparticle-based drug delivery system for the treatment of inflammatory bowel disease","volume":"140","author":"Shrestha","year":"2022","journal-title":"Acta Biomater."},{"key":"ref_118","doi-asserted-by":"crossref","unstructured":"Ly, P.D., Ly, K.N., Phan, H.L., Nguyen, H.H.T., Duong, V.A., and Nguyen, H.V. (2024). Recent advances in surface decoration of nanoparticles in drug delivery. Front. Nanotechnol., 6.","DOI":"10.3389\/fnano.2024.1456939"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"2000165","DOI":"10.1002\/adtp.202000165","article-title":"One-Pot Synthesis of pH-Responsive Eudragit-Mesoporous Silica Nanocomposites Enable Colonic Delivery of Glucocorticoids for the Treatment of Inflammatory Bowel Disease","volume":"4","author":"Qu","year":"2021","journal-title":"Adv. Ther."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"122741","DOI":"10.1016\/j.ijpharm.2023.122741","article-title":"Colon-specific delivery of methotrexate using hyaluronic acid modified pH-responsive nanocarrier for the therapy of colitis in mice","volume":"635","author":"Lv","year":"2023","journal-title":"Int. J. Pharm."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Wang, J., Yao, M., Zou, J., Ding, W., Sun, M., Zhuge, Y., and Gao, F. (2023). pH-sensitive nanoparticles for colonic delivery anti-miR-301a in mouse models of inflammatory bowel diseases. Nanomaterials, 13.","DOI":"10.3390\/nano13202797"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1007\/s00424-024-02943-y","article-title":"Role of pH-sensing receptors in colitis","volume":"476","author":"Hausmann","year":"2024","journal-title":"Pflug. Arch."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Yamamura, R., Inoue, K.Y., Nishino, K., and Yamasaki, S. (2023). Intestinal and fecal pH in human health. Front. Microbiomes, 2.","DOI":"10.3389\/frmbi.2023.1192316"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1136\/gut.48.4.571","article-title":"Intestinal luminal pH in inflammatory bowel disease: Possible determinants and implications for therapy with aminosalicylates and other drugs","volume":"48","author":"Nugent","year":"2001","journal-title":"Gut"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"5409","DOI":"10.1007\/s12274-024-6435-6","article-title":"ROS-responsive nanoparticles targeting inflamed colon for synergistic therapy of inflammatory bowel disease via barrier repair and anti-inflammation","volume":"17","author":"Wang","year":"2024","journal-title":"Nano Res."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"106856","DOI":"10.1016\/j.ejps.2024.106856","article-title":"ROS-responsive thioketal nanoparticles delivering system for targeted ulcerative colitis therapy with potent HDAC6 inhibitor, tubastatin A","volume":"201","author":"Shrestha","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2411979","DOI":"10.1002\/adfm.202411979","article-title":"Reactive oxygen species triggered cleavage of thioketal-containing supramolecular nanoparticles for inflammation-targeted oral therapy in ulcerative colitis","volume":"35","author":"Xiong","year":"2025","journal-title":"Adv. Funct. Mater."},{"key":"ref_128","doi-asserted-by":"crossref","unstructured":"Rinaldi, A., Caraffi, R., Grazioli, M.V., Oddone, N., Giardino, L., Tosi, G., Vandelli, M.A., Calz\u00e0, L., Ruozi, B., and Duskey, J.T. (2022). Applications of the ROS-responsive thioketal linker for the production of smart nanomedicines. Polymers, 14.","DOI":"10.3390\/polym14040687"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"eabj2372","DOI":"10.1126\/sciadv.abj2372","article-title":"A nanoparticulate dual scavenger for targeted therapy of inflammatory bowel disease","volume":"8","author":"Shi","year":"2022","journal-title":"Sci. Adv."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"2551","DOI":"10.1038\/s41467-025-57890-8","article-title":"Biosilicification-mimicking chiral nanostructures for targeted treatment of inflammatory bowel disease","volume":"16","author":"Xu","year":"2025","journal-title":"Nat. Commun."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1186\/s12951-024-02749-1","article-title":"Oral enzyme-responsive nanoprobes for targeted theranostics of inflammatory bowel disease","volume":"22","author":"Cao","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1186\/s40580-024-00414-9","article-title":"Polymeric DNase-I nanozymes targeting neutrophil extracellular traps for the treatment of bowel inflammation","volume":"11","author":"Wang","year":"2024","journal-title":"Nano Converg."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"2301585","DOI":"10.1002\/adma.202301585","article-title":"Efficient therapy of inflammatory bowel disease (IBD) with highly specific and durable targeted Ta2C modified with chondroitin sulfate (TACS)","volume":"35","author":"Song","year":"2023","journal-title":"Adv. Mater."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1093\/ibd\/izab193","article-title":"Antitumor necrosis factor-like ligand 1A therapy Targets Tissue Inflammation and Fibrosis Pathways and Reduces Gut Pathobionts in Ulcerative Colitis","volume":"28","author":"Ye","year":"2022","journal-title":"Inflamm. Bowel Dis."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"2400439","DOI":"10.1002\/adtp.202400439","article-title":"Pathophysiology of IBD as a key strategy for polymeric nanoparticle development","volume":"8","author":"Gardey","year":"2025","journal-title":"Adv. Ther."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Zhang, D., Jiang, L., Yu, F., Yan, P., Liu, Y., Wu, Y., and Yang, X. (2024). PepT1-targeted nanodrug based on co-assembly of anti-inflammatory peptide and immunosuppressant for combined treatment of acute and chronic DSS-induced colitis. Front. Pharmacol., 15.","DOI":"10.3389\/fphar.2024.1442876"},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"121976","DOI":"10.1016\/j.biomaterials.2022.121976","article-title":"Orally deliverable sequence-targeted astaxanthin nanoparticles for colitis alleviation","volume":"293","author":"Chen","year":"2023","journal-title":"Biomaterials"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1186\/s12967-024-05682-x","article-title":"Berberine-loaded PLGA nanoparticles alleviate ulcerative colitis by targeting IL-6\/IL-6R axis","volume":"22","author":"Liu","year":"2024","journal-title":"J. Transl. Med."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"14914","DOI":"10.1021\/acsnano.5c00355","article-title":"Somatostatin and mannooligosaccharide modified selenium nanoparticles with dual-targeting for ulcerative colitis treatment","volume":"19","author":"Ye","year":"2025","journal-title":"ACS Nano"},{"key":"ref_140","doi-asserted-by":"crossref","unstructured":"Ismail, J., Klepsch, L.C., Dahlke, P., Tsarenko, E., Vollrath, A., Pretzel, D., Jordan, P.M., Rezaei, K., Czaplewska, J.A., and Stumpf, S. (2024). PEG\u2013Lipid\u2013PLGA hybrid particles for targeted delivery of anti-inflammatory drugs. Pharmaceutics, 16.","DOI":"10.3390\/pharmaceutics16020187"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1186\/s12951-024-02861-2","article-title":"Mannose coated selenium nanoparticles normalize intestinal homeostasis in mice and mitigate colitis by inhibiting NF-\u03baB activation and enhancing glutathione peroxidase expression","volume":"22","author":"Yang","year":"2024","journal-title":"J. Nanobiotechnol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"528","DOI":"10.7150\/thno.87739","article-title":"Targeted modulation of intestinal epithelial regeneration and immune response in ulcerative colitis using dual-targeting bilirubin nanoparticles","volume":"14","author":"Zhuo","year":"2024","journal-title":"Theranostics"},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"112448","DOI":"10.1016\/j.isci.2025.112448","article-title":"Inflammatory targeted nanoplatform incorporated with antioxidative nano iron oxide to attenuate ulcerative colitis progression","volume":"28","author":"Chen","year":"2025","journal-title":"iScience"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1007\/s13346-024-01736-1","article-title":"Dual action tofacitinib-loaded PLGA nanoparticles alleviate colitis in an IBD mouse model","volume":"15","author":"Seegobin","year":"2025","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_145","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.ijbiomac.2020.12.094","article-title":"Macrophages-targeting mannosylated nanoparticles based on inulin for the treatment of inflammatory bowel disease (IBD)","volume":"169","author":"Sun","year":"2021","journal-title":"Int. J. Biol. Macromol."},{"key":"ref_146","doi-asserted-by":"crossref","unstructured":"Mow, R.J., Kuczma, M.P., Shi, X., Mani, S., Merlin, D., and Yang, C. (2024). Harnessing a safe novel lipid nanoparticle: Targeted oral delivery to colonic epithelial and macrophage cells in a colitis mouse model. Nanomaterials, 14.","DOI":"10.3390\/nano14221800"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"22901","DOI":"10.1021\/acsnano.3c08030","article-title":"MicroRNA-200 loaded lipid nanoparticles promote intestinal epithelium regeneration in canonical microRNA-deficient mice","volume":"17","author":"Wei","year":"2023","journal-title":"ACS Nano"},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"433","DOI":"10.1016\/j.chom.2023.01.006","article-title":"Autophagy controls mucus secretion from intestinal goblet cells by alleviating ER stress","volume":"31","author":"Naama","year":"2023","journal-title":"Cell Host Microbe"},{"key":"ref_149","doi-asserted-by":"crossref","first-page":"0102","DOI":"10.34133\/bmr.0102","article-title":"Cell Membrane-Coated Nanotherapeutics for the targeted treatment of acute and chronic colitis","volume":"28","author":"Li","year":"2024","journal-title":"Biomater. Res."},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"9322282","DOI":"10.1155\/2021\/9322282","article-title":"Safety and toxicity issues of therapeutically used nanoparticles from the oral route","volume":"2021","author":"Lotfipour","year":"2021","journal-title":"BioMed Res. Int."},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"103485","DOI":"10.1016\/j.etap.2020.103485","article-title":"Toxic effects of the food additives titanium dioxide and silica on the murine intestinal tract: Mechanisms related to intestinal barrier dysfunction involved by gut microbiota","volume":"80","author":"Yan","year":"2020","journal-title":"Environ. Toxicol. Pharmacol."},{"key":"ref_152","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1007\/s00204-020-02694-6","article-title":"Small silica nanoparticles transiently modulate the intestinal permeability by actin cytoskeleton disruption in both Caco-2 and Caco-2\/HT29-MTX models","volume":"94","author":"Cornu","year":"2020","journal-title":"Arch. Toxicol."},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12989-017-0226-0","article-title":"The unrecognized occupational relevance of the interaction between engineered nanomaterials and the gastro-intestinal tract: A consensus paper from a multidisciplinary working group","volume":"14","author":"Pietroiusti","year":"2017","journal-title":"Part. Fibre Toxicol."},{"key":"ref_154","doi-asserted-by":"crossref","unstructured":"Najahi-Missaoui, W., Arnold, R.D., and Cummings, B.S. (2020). Safe nanoparticles: Are we there yet?. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms22010385"},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"101726","DOI":"10.1016\/j.cocis.2023.101726","article-title":"Immune-active polymeric materials for the treatment of inflammatory diseases","volume":"67","author":"Lazar","year":"2023","journal-title":"Curr. Opin. Colloid Interface Sci."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1016\/j.jconrel.2024.11.070","article-title":"Establishment of a 3D multi-layered in vitro model of inflammatory bowel disease","volume":"377","author":"Ferreira","year":"2025","journal-title":"J. Controll. Release"},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"8875","DOI":"10.2147\/IJN.S210315","article-title":"Nanoparticle-mediated drug delivery systems for the treatment of IBD: Current perspectives","volume":"14","author":"Yang","year":"2019","journal-title":"Int. J. Nanomed."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.actbio.2024.09.007","article-title":"Stimulus-responsive drug delivery nanoplatforms for inflammatory bowel disease therapy","volume":"188","author":"Long","year":"2024","journal-title":"Acta Biomater."},{"key":"ref_159","doi-asserted-by":"crossref","unstructured":"Tan, A.X.X., Ong, B.Y.C., Dinesh, T., and Srinivasan, D.K. (2025). Nanomedicine strategies in the management of inflammatory bowel disease and colorectal cancer. Int. J. Mol. Sci., 26.","DOI":"10.20944\/preprints202506.0784.v1"},{"key":"ref_160","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1007\/s13346-020-00740-5","article-title":"Challenges in nanomedicine clinical translation","volume":"10","author":"Metselaar","year":"2020","journal-title":"Drug Deliv. Transl. Res."},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"1597","DOI":"10.1038\/s41565-024-01754-7","article-title":"A translational framework to deliver nanomedicines to the clinic","volume":"19","author":"Joyce","year":"2024","journal-title":"Nat. Nanotechnol."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/1\/55\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,31]],"date-time":"2025-12-31T16:37:42Z","timestamp":1767199062000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/18\/1\/55"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12,31]]},"references-count":161,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,1]]}},"alternative-id":["pharmaceutics18010055"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics18010055","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12,31]]}}}